Heart Failure October 3, 2024

EMBARK-HFpEF Trial Flexes Mavacamten’s HF Potential October 3, 2024

A new HFpEF treatment might be on the horizon, after results from the EMBARK-HFpEF trial showed that BMS’ hypertrophic cardiomyopathy treatment, mavacamten (Camzyos), safely improved key HFpEF symptoms and biomarkers. To test mavacamten’s HFpEF potential, the open-label Phase 2a EMBARK-HFpEF trial treated 30 HFpEF patients with mavacamten (avg age 76, NYHA Class II & III, […]

Preventive Cardiology September 30, 2024

Cancer’s CVD Risks and SGLT2is’ Preventative Potential September 30, 2024

Better treatments have led to improved cancer survival rates, but new research reveals increased cardiovascular complications in survivors. However, another new study offers hope, suggesting that heart medications like SGLT2 inhibitors may help prevent cancer-related heart disease. A new Cancer Journal study showed that older cancer survivors have far higher rates of cardiovascular events than […]

Heart Failure September 26, 2024

Windtree’s Istaroxime Scores in Cardiogenic Shock Trial September 26, 2024

Windtree Therapeutics’ istaroxime appears to have scored in its latest Phase 2b trial, showing that the steroidal drug significantly improves systolic blood pressure in cardiogenic shock patients. The Phase 2b SEISMiC extension trial evaluated istaroxime infusions for up to 60 hours in patients with early-stage cardiogenic shock, measuring its impact during the first 96 hours […]

Pharmaceuticals September 23, 2024

Edgewise Therapeutics’ EDG-7500 Emerges as New HCM Contender September 23, 2024

A new HCM competitor emerged last week, after Edgewise Therapeutics’ EDG-7500 showed strong evidence of its safety and efficacy in a pair of early-stage trials. Edgewise tested EDG-7500 in a Phase 1 trial to confirm the drug’s side effects, and an early part of a Phase 2 trial to measure EDG-7500’s impact on key oHCM […]

More Stories

Surgeries & Interventions September 19, 2024

Questioning PCI’s Left Ventricular Dysfunction Effect September 19, 2024

New analysis of the REVIVED-BCIS2 trial adds more evidence that PCI has limited impact in patients with left ventricular dysfunction, even when you include quality of life and overall health status. The secondary analysis of the REVIVED-BCIS2 trial examined outcomes from 700 patients with severe ischemic left ventricular systolic dysfunction (median age: 70yrs; mean LVEF: […]

Hypertension September 16, 2024

America’s Hypertension Awareness and Control Problem September 16, 2024

Nearly half of American adults have hypertension, and a new JAMA study reveals that the vast majority of them don’t have their blood pressure under control, while most don’t even know they have the disease. To better understand our hypertension control challenges, a CDC team analyzed 2017-2020 NHANES survey data featuring 7,328 U.S. adults (3,954 […]

Atrial Fibrillation September 12, 2024

AFib Might Be Far More Common Than We Think September 12, 2024

A JACC study suggests that atrial fibrillation is far more prevalent than many previously thought, estimating that nearly one in 20 American adults have been diagnosed with the disease. UCSF researchers analyzed medical records from 29M adults who received hospital-based care in California from 2005 to 2019 (51yr avg. age, 54% women, 50% White), finding […]

Pharmaceuticals September 9, 2024

Questioning Beta-Blocker Interruption After Heart Attack September 9, 2024

Results from the ABYSS trial surprised many at ESC 2024, finding that patients who continue beta-blocker therapy after heart attacks have better long-term outcomes than patients who stop taking the drugs, and they don’t experience the quality of life downsides that some might expect. 

Atrial Fibrillation September 5, 2024

Burn the Ships? What OCEANIC-AF Means for Asundexian and Factor XI September 5, 2024

Nearly a year after Bayer halted its OCEANIC-AF trial, the study’s ESC 2024 presentation revealed new insights into asundexian’s AFib stroke-prevention challenges and what they might mean for Factor XI inhibitors.

Pharmaceuticals September 3, 2024

Alylam’s Vutrisiran Shines in HELIOS-B Trial September 3, 2024

Alylam’s vutrisiran dominated early ESC 2024 headlines and conversations, after full results from the Phase 3 HELIOS-B trial highlighted its significant impact on transthyretin amyloidosis with cardiomyopathy (ATTR-CM).

Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like..

Select All

You're signed up!

It's great to have you as a reader. Check your inbox for a welcome email.

-- The Cardiac Wire Team

You're all set!